Lexology March 22, 2024
As directed by the Inflation Reduction Act (IRA), the Centers for Medicare and Medicaid Services (CMS) will set prices for certain drugs in Medicare Parts B and D through the Medicare Drug Price Negotiation Program (MDNP).[1] The negotiated prices for the first ten drugs selected is scheduled to go into effect in 2026.
In this alert, we evaluate the pre-IRA formulary position and cost sharing in the two types of Medicare drug plans for the ten selected drugs and offer considerations for how patient cost may be affected by the MDNP in 2026.
About our analysis
Our formulary analysis suggests that for seven of the ten selected drugs, Medicare beneficiaries will not likely see a significant change in their cost...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech